Why Is G1 Therapeutics (GTHX) Stock Down 56% Today?

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

G1 Therapeutics stock is down on Monday as GTHX investors react to the company's Phase 3 clinical trial of trilaciclib failing.

The post Why Is G1 Therapeutics (GTHX) Stock Down 56% Today? appeared first on InvestorPlace.

More From InvestorPlace

• The #1 AI Investment Might Be This Company You’ve Never Heard Of
• Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
• Legendary Investor Predicts: “Forget A.I. THIS Technology Is the Future”